Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Non-Current Liabilities (2018 - 2025)

Sangamo Therapeutics has reported Total Non-Current Liabilities over the past 10 years, most recently at $73.4 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $73.4 million for Q4 2025, down 5.77% from a year ago — trailing twelve months through Dec 2025 was $73.4 million (down 5.77% YoY), and the annual figure for FY2025 was $73.4 million, down 5.77%.
  • Total Non-Current Liabilities for Q4 2025 was $73.4 million at Sangamo Therapeutics, down from $81.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for SGMO hit a ceiling of $400.4 million in Q1 2021 and a floor of $68.1 million in Q2 2024.
  • Median Total Non-Current Liabilities over the past 5 years was $86.8 million (2023), compared with a mean of $180.6 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 117.66% in 2021 and later crashed 70.56% in 2023.
  • Sangamo Therapeutics' Total Non-Current Liabilities stood at $345.4 million in 2021, then dropped by 22.88% to $266.3 million in 2022, then crashed by 69.5% to $81.2 million in 2023, then fell by 4.08% to $77.9 million in 2024, then decreased by 5.77% to $73.4 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $73.4 million (Q4 2025), $81.4 million (Q3 2025), and $77.0 million (Q2 2025) per Business Quant data.